hyperphosphatemia

News

FDA panel backs Ardelyx CKD drug, despite agency concerns

While the FDA seems to remain sceptical about the clinical benefits of Ardelyx's chronic kidney disease (CKD) therapy Xphozah – having

News

Hard times at Ardelyx as FDA rejects kidney disease drug ten...

The FDA has taken a longer than usual look at Ardelyx's regulatory submission for tenapanor, a drug for high blood phosphate levels associated with chronic kidney disease (CKD), and found i

Views & Analysis

Ardelyx’s ambition to revolutionise kidney treatment

A therapy to treat hyperphosphatemia is moving closer to the market after years of development by California-based company Ardelyx.

FDA panel backs Ardelyx CKD drug, despite agency concerns

Hard times at Ardelyx as FDA rejects kidney disease drug ten...

Ardelyx’s ambition to revolutionise kidney treatment

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks